Abstract
We have studied the pharmacokinetics of methotrexate in patients with rheumatoid arthritis concurrently taking the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, diclofenac, naproxen, indomethacin, and ibuprofen. The area under the curve, the total systemic clearance, the distribution volume, and the half-life of methotrexate in patients receiving concurrent NSAID therapy did not change significantly (at p < 0.05). Concurrent treatment with NSAIDs resulted in increased inter-patient variability of methotrexate concentration, possibly as a result of biochemical interactions; however, it does not appear clinically relevant. The data suggest that the NSAIDs do not significantly affect the disposition of methotrexate, contrary to some of the earlier reports.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 163-167 |
| Number of pages | 5 |
| Journal | Biopharmaceutics and Drug Disposition |
| Volume | 19 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1998 |
Keywords
- Adverse effects
- Disposition
- Interaction
- Methotrexate
- Non-steroidal inflammatory drugs (NSAIDs)
- Pharmacokinetics